Latest Insider Transactions at Xenon Pharmaceuticals Inc. (XENE)
This section provides a real-time view of insider transactions for Xenon Pharmaceuticals Inc. (XENE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Xenon Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Xenon Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 22
2024
|
Gary Patou |
SELL
Open market or private sale
|
Direct |
4,891
-9.38%
|
$200,531
$41.08 P/Share
|
|
Nov 22
2024
|
Gary Patou |
SELL
Payment of exercise price or tax liability
|
Direct |
1,695
-3.16%
|
$66,105
$39.8 P/Share
|
|
Nov 22
2024
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
6,586
+10.91%
|
$65,860
$10.43 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
SELL
Open market or private sale
|
Direct |
2,092
-100.0%
|
$94,140
$45.69 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
SELL
Payment of exercise price or tax liability
|
Direct |
1,408
-40.23%
|
$64,768
$46.16 P/Share
|
|
Mar 08
2024
|
Elizabeth A. Garofalo |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+50.0%
|
$63,000
$18.56 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
7,137
-24.35%
|
$328,302
$46.23 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
1,504
-4.95%
|
$67,680
$45.96 P/Share
|
|
Mar 07
2024
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
8,641
+20.96%
|
$77,769
$9.85 P/Share
|
|
Mar 07
2024
|
Steven Gannon |
SELL
Open market or private sale
|
Direct |
13,000
-36.98%
|
$598,000
$46.3 P/Share
|
|
Dec 29
2023
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Other acquisition or disposition
|
Direct |
8,398
-50.0%
|
-
|
|
Dec 19
2023
|
Mohammad Azab |
BUY
Exercise of conversion of derivative security
|
Direct |
4,320
+2.82%
|
$38,880
$9.85 P/Share
|
|
Dec 13
2023
|
Gary Patou |
SELL
Open market or private sale
|
Indirect |
7,598
-60.78%
|
$311,518
$41.05 P/Share
|
|
Dec 13
2023
|
Gary Patou |
SELL
Open market or private sale
|
Direct |
11,380
-13.71%
|
$443,820
$39.29 P/Share
|
|
Dec 13
2023
|
Gary Patou |
SELL
Payment of exercise price or tax liability
|
Direct |
3,022
-3.5%
|
$117,858
$39.68 P/Share
|
|
Dec 13
2023
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
14,402
+14.19%
|
$129,618
$9.57 P/Share
|
|
Aug 24
2023
|
Dawn Svoronos |
SELL
Open market or private sale
|
Direct |
25,000
-50.0%
|
$950,000
$38.7 P/Share
|
|
Jun 01
2023
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
31,713
-67.79%
|
$1,205,094
$38.88 P/Share
|
|
Jun 01
2023
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
22,605
-26.41%
|
$858,990
$38.53 P/Share
|
|
Jun 01
2023
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
54,318
+42.35%
|
$651,816
$12.73 P/Share
|
|
May 31
2023
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
62,526
-76.06%
|
$2,375,988
$38.68 P/Share
|
|
May 31
2023
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
29,309
-29.27%
|
$1,113,742
$38.37 P/Share
|
|
May 31
2023
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
79,835
+46.3%
|
$1,037,855
$13.81 P/Share
|
|
May 30
2023
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
37,006
-42.04%
|
$1,443,234
$39.27 P/Share
|
|
May 24
2023
|
Ian Mortimer PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
31,655
-25.96%
|
$1,297,855
$41.43 P/Share
|
|
May 24
2023
|
Ian Mortimer PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,383
-9.07%
|
$507,703
$41.84 P/Share
|
|
May 24
2023
|
Ian Mortimer PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
69,340
+31.2%
|
$624,060
$9.71 P/Share
|
|
Mar 24
2023
|
Christopher John Kenney Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
700
-100.0%
|
$24,500
$35.01 P/Share
|
|
Mar 07
2023
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
19,232
-18.73%
|
$692,352
$36.97 P/Share
|
|
Mar 07
2023
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
3,778
-3.54%
|
$139,786
$37.13 P/Share
|
|
Mar 07
2023
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
72,016
+39.42%
|
$144,032
$2.64 P/Share
|
|
Dec 12
2022
|
Mohammad Azab |
BUY
Exercise of conversion of derivative security
|
Direct |
3,086
+4.23%
|
$6,172
$2.68 P/Share
|
|
Nov 25
2022
|
Gary Patou |
SELL
Open market or private sale
|
Direct |
1,937
-7.59%
|
$65,858
$34.79 P/Share
|
|
Nov 25
2022
|
Gary Patou |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-0.47%
|
$4,080
$34.37 P/Share
|
|
Nov 25
2022
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
2,057
+7.43%
|
$4,114
$2.68 P/Share
|
|
Nov 23
2022
|
Gary Patou |
SELL
Open market or private sale
|
Direct |
2,057
-8.03%
|
$69,938
$34.33 P/Share
|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,355
-100.0%
|
$598,845
$39.57 P/Share
|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,293
-17.66%
|
$128,427
$39.53 P/Share
|
|
Sep 02
2022
|
Sherry Aulin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,648
+19.95%
|
$111,888
$6.64 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
43,879
-46.09%
|
$1,667,402
$38.41 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
6,121
-9.16%
|
$232,598
$38.81 P/Share
|
|
Sep 01
2022
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+42.81%
|
$200,000
$4.75 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
21,352
-55.97%
|
$811,376
$38.57 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
1,572
-3.96%
|
$58,164
$37.86 P/Share
|
|
Aug 31
2022
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
22,488
+22.34%
|
$67,464
$3.71 P/Share
|
|
Aug 16
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
52,058
-66.07%
|
$1,978,204
$38.58 P/Share
|
|
Aug 15
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
33,942
-36.89%
|
$1,255,854
$37.76 P/Share
|
|
Aug 12
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
91,135
-19.4%
|
$3,463,130
$38.55 P/Share
|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Open market or private sale
|
Direct |
57,743
-60.79%
|
$2,194,234
$38.38 P/Share
|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
7,257
-9.68%
|
$275,766
$38.02 P/Share
|